Showing results (91-100 of 154) with videos related to

Sort By:
Pageof 16
Blood|September 19, 2025
FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AMLReeja Raj, Samanta Catueno, Amber Gibson, et al.
British Journal of Haematology|August 23, 2023
Phenotypic subtypes of leukaemic transformation in chronic myelomonocytic leukaemiaGuillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Ziyi Li, et al.
American Journal of Hematology|May 22, 2025
A Phase 2 Trial of CPX-351 Combined With Venetoclax in Relapsed or Refractory Acute Myeloid LeukemiaTapan M Kadia, Wei-Ying Jen, Alex Bataller, et al.
Leukemia|May 9, 2025
Characteristics and outcomes of newly diagnosed acute myeloid Leukemia with KMT2A rearrangementsAlex Bataller, Hannah E Goulart, Ghayas C Issa, et al.
Cancer|October 4, 2016
Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual diseaseGhayas C Issa, Hagop M Kantarjian, C Cameron Yin, et al.
Blood|July 13, 2023
Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemiaJayastu Senapati, Samuel Urrutia, Sanam Loghavi, et al.
Haematologica|May 2, 2024
Outcomes and genetic dynamics of acute myeloid leukemia at first relapseAlex Bataller, Hagop Kantarjian, Alexandre Bazinet, et al.
American Journal of Hematology|September 2, 2022
Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD-negative remissionNicholas J Short, Walid Macaron, Tapan Kadia, et al.
The New England Journal of Medicine|May 31, 2024
Asciminib in Newly Diagnosed Chronic Myeloid LeukemiaAndreas Hochhaus, Jianxiang Wang, Dong-Wook Kim, et al.
Journal of Hematology & Oncology|June 27, 2026
Vibecotamab for measurable residual disease in acute myeloid leukemia and for myelodysplastic syndromes and chronic myelomonocytic leukemia after hypomethylating agent failure: a phase II studyNicholas J Short, Alex Bataller, Courtney D DiNardo, et al.
Pageof 16